4:02 PM ET
8-K
Capital Raise
Gossamer Bio Capital Raise
Gossamer Bio stockholders approved the potential issuance of common stock exceeding 20% of outstanding shares in connection with a Securities Purchase Agreement dated August 20, 2026. The approval covers shares issuable upon the exercise of Pre-Funded Warrants, FDA Approval Warrants, and the conversion of Series A-1, A-2, and A-3 Preferred Stock, satisfying Nasdaq Listing Rules 5635(c) and 5635(d).